Recent Updates
Recently added Catalysts
FULC

Fulcrum Therapeutics to Participate at Upcoming November Investor Conferences

Key Takeaway: CAMBRIDGE, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in the fol

Full Press Release Details

CAMBRIDGE, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in the following upcoming investor conferences:
Credit Suisse 31st Annual Healthcare Conference
Tuesday, November 8, 2022 at 2:35 p.m. PT (Fireside Chat)
Piper Sandler 34th Annual Healthcare Conference
Tuesday, November 29, 2022 at 4:30 p.m. ET (Fireside Chat)
Live audio webcasts of the presentations will be available through the Investor Relations section of the Fulcrum website at https://ir.fulcrumtx.com/events-and-presentations. An archived replay will be available on the Company’s website for 30 days.
About Fulcrum Therapeutics
Stern Investor Relations, Inc.
Executive Director, Corporate Communications
Fulcrum Therapeutics, Inc.
Last updated: Nov 1, 2022